Oh, the irony! Here we have doxycycline, the antibiotic knight in shining armor, hailed for its anti-inflammatory prowess, ready to charge into battle against the dragon of abdominal aortic aneurysm (AAA) growth. But wait—plot twist! It turns out our hero has a dark side: mitochondrial dysfunction in the aorta and aortic smooth muscle cells (SMCs). Who would’ve thought?

So, our intrepid researchers, armed with the power of hypothesis, ventured forth to uncover the truth. They discovered that doxycycline, while trying to save the day, actually causes a mitonuclear imbalance, stunts cell proliferation, and makes SMCs forget how to be muscular. It’s like going to the gym and instead of getting buff, you just get tired and cranky.

But fear not, for the plot thickens with the introduction of krüppel-like factor 4 (KLF4), a transcription factor that apparently gets all hyped up after doxycycline treatment. Yet, when they silenced KLF4, it was like a movie without a soundtrack—nothing changed. The SMCs still lost their mojo.

Enter elamipretide (SS-31), the bioenergetics drug with a name that sounds like a Star Wars droid. This little guy didn’t get the SMCs back in shape, but it did throw them a mitochondrial lifeline, improving their genes and social network (a.k.a. connectivity).

In conclusion, while doxycycline might be good at putting out the inflammatory fire, it’s also sneakily cutting the power to the mitochondrial powerhouse, potentially making AAA worse. But hey, elamipretide might just be the sidekick we need to keep the lights on. Who’s ready for a sequel?